Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-11-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | http://oncourology.abvpress.ru/index.php/oncur/article/view/383 |